{
  "docId": "019de072-0fef-7225-bee8-4eafefc8a1ee",
  "docSlug": "7f14a86c142f5693f0e80c8dcf59a0d2",
  "documentTitle": "23andMe | Investor Presentation Deck | 63 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 63,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a split-screen layout with a gradient background on the left and key bullet points on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0fef-7225-bee8-4eafefc8a1ee/42",
  "deckHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee",
  "deckJsonHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee.json",
  "deckAnchorHref": "/decks/019de072-0fef-7225-bee8-4eafefc8a1ee#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.08,
        "x": 0.02,
        "y": 0.085
      },
      "kind": "image",
      "text": "Partnered with gsk",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "563d23ee-be3c-4d6e-8f78-bdff485b7536",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.44,
        "x": 0.53,
        "y": 0.12
      },
      "kind": "list",
      "text": "CD96 is Part of the genetically-validated CD226 axis that is associated with cancer and autoimmunity\nInhibition of CD96 leads to immune activation and tumor growth inhibition in non-clinical models\nGSK6097608 (GSK'608) is a high affinity monoclonal antibody against CD96\nFurther clinical development will focus on extending the benefit of GSK'608 in combination with other I/O therapies\nPhase 1 data for GSK6097608 is anticipated in 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b67dbb07-1747-434d-9522-1a349bc4f0f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.06,
        "y": 0.18
      },
      "kind": "title",
      "text": "GSK'608 Targeting CD96: A Genetically-Validated Approach to Anti-Cancer Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87003092-b09a-48fe-8f04-75d9ffce0111",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "f1818817-0ab7-4a92-8b82-9ccf53958b38",
      "evidence": "Although not a traditional 2x2 matrix, the slide presents a clear framework for understanding the CD226 axis and GSK'608's role in it.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}